• 

  Immune molecule may drive excessive drinking in alcohol use disorder

  Scripps Research scientists showed that blocking an immune molecule tied to inflammation reduced alcohol consumption in mice.

• 

  Back in action: Researchers make drug-resistant bacteria vulnerable again

  New findings from Scripps Research show that disabling a single bacterial protein can restore vancomycin’s power against resistant bacteria–and point to a new strategy for overcoming antibiotic resistance.

• 

  Newly identified molecule strengthens the eye’s response to damage in retinal disease

  Scripps Research discovery finds that restoring the naturally occurring compound erucamide in the eye stabilized tissue in preclinical models of retinal degeneration.

• 

  Lab studies explain how new cancer drug works as it enters patient testing

  Immunologists at Scripps Research show how a new, experimental drug revives immune cells to fight cancer.

• 

  Calibr-Skaggs awarded $5.1M by NIH to develop long-acting hepatitis B virus therapy

  A new program aims to replace a daily HBV drug with once-monthly—or even quarterly—injections for people managing both HIV and HBV.

• 

  Two Scripps Research assistant professors named 2026 Baxter Young Investigators

  The Baxter Foundation annually support early-career researchers whose work in science and technology holds promise for improving patient care.

• 

  A fentanyl countermeasure that adapts to combat future black-market drugs

  Scripps Research scientists developed a vaccine that teaches the immune system to rapidly neutralize fentanyl and new emerging synthetic fentanyl analogs.

• 

  Chemists snap together complex 3D molecules from highly reactive ‘radicals’—without losing their shape

  Scripps Research team develops stereoretentive radical-radical cross-coupling, a simpler way to build chiral drug candidates.

• 

  Calibr-Skaggs advances CLF065, a regenerative GLP-2 therapy, into two Phase 2 IBD studies

  CLF065, a long-acting, once-weekly GLP-2 receptor agonist, advances in two inflammatory bowel disease indications. The studies aim to bring a regenerative treatment option to patients living with IBD, who currently have few therapies that repair the damaged intestinal lining at the root of their disease.

• 

  Experimental HIV vaccine achieves a long-sought goal

  In a first for the field, all non-human primates given a new series of vaccines generated antibodies capable of fighting multiple strains of HIV.